Loading data for CNSP — first visit, this takes a few seconds.
CNS Pharmaceuticals, Inc.
5.73 -0.16 (-2.72%)
5.78 -1.03%
- Market Cap
- $8.53M
- Volume
- 4.75K
- Dividend yield
- n/a
CNS Pharmaceuticals, Inc. (CNSP) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $0 | n/a | n/a |
| EPS | -$0,38 | -$0,14 | +94.08% |
Metrics
- Bid
- 4.04
- Market Cap
- 8.53M
- Revenue (ttm)
- n/a
- Net Income (ttm)
- -16.7M
- 1.00
- -15.39
- n/a
- -14.97
- P/B (ttm)
- 0.47
- P/S (ttm)
- n/a
- Earnings Date
- n/a
- Ask
- 7.68
- Volume
- 4,746
- Avg. Volume (20D)
- 10,777
- Open
- 5.90
- Previous Close
- 5.89
- Day's Range
- 5.73 - 5.90
- 52-Week Range
- 1.90 - 10.59
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About CNS Pharmaceuticals, Inc.
View profile →CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 2019
Employees 8
Stock Exchange NasdaqCM
Ticker Symbol CNSP
Website https://cnspharma.com